Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financi...( SEATTLE Nov. 8 /- Cell Therapeuti...),Health

SEATTLE, Nov. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today reported recent accomplishments and financial results for the quarter and nine months ended September 30, 2007.

Recent Events

-- Announced agreement to acquire ZEVALIN(R) (ibritumomab tiuxetan), the

first FDA-approved radioimmunotherapy, from Biogen Idec; this

acquisition, if completed, will return CTI to a select group of only a

few biotech companies which market and sell a commercial product

-- Announced a potential abbreviated registration path for pixantrone

based on the Company's decision to do a full analysis of the EXTEND

(PIX301) phase III clinical trial for patients with relapsed,

aggressive non-Hodgkin's lymphoma (NHL), which is targeted for data

release in mid-2008

-- Added brostallicin, a novel phase II cancer drug candidate to CTI's

portfolio through its acquisition of Systems Medicine Inc., a privately

held company connected with the Translational Genomics Research

Institute

-- Added Richard L. Love, former founder and CEO of Triton Biosciences

Inc. and ILEX Oncology, Inc. to its board of directors

-- Received special protocol assessment (SPA) approval of and launched a

phase III clinical trial, known as PIX303, of pixantrone for patients

with indolent NHL who have relapsed following first-line therapy

-- Received SPA approval of and launched a confirmatory phase III clinical

trial, known as PGT307, of XYOTAX(TM) (paclitaxel poliglumex, CT-2103)

in combination with carboplatin for women with pre-menopausal estrogen

levels who have advanced non-small cell lung cancer (NSCLC)

"Our acquisition of Systems Medicine, Inc. and our proposed acquisition of ZEVALIN, coupled with progress on advancing XYOTAX toward a first half 2008 marketing application submission a
'/>"/>